dr. robson on the toxicity profile of olaparib in breast cancer
Published 6 years ago • 348 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
1:18
dr. robson on exploratory analysis from olympiad in breast cancer
-
1:36
dr. robson on the application of precision medicine in breast cancer
-
1:23
dr. robertson on olaparib for serous ovarian cancer
-
1:30
dr. agarwal on the safety profile of olaparib in hrr gene-mutant mcrpc
-
1:10
dr. tripathy on impact of olaparib approval in brca-positive breast cancer
-
0:49
dr. tung discusses the role of olaparib in breast cancer
-
1:15
dr. jane robertson on the mechanism of action of olaparib
-
3:05
exploring the use of olaparib in advanced breast cancer
-
0:40
dr. willmott on fda approval of maintenance olaparib in ovarian cancer
-
3:31
distinguishing between parp inhibitors in breast cancer
-
5:43
using olaparib in gbrca1/2 breast cancer
-
11:22
olaparib in ovarian cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
1:27
dr. litton on the impact of parp inhibitors in breast cancer
-
2:46
dr. brufsky on the fda approval of olaparib in brca breast cancer
-
2:21
olaparib: predicting response in breast cancer
-
6:18
value of olaparib in brca-mutated advanced ovarian cancer
-
2:44
olympia: adjuvant olaparib in gbrcam, her2-negative, high-risk, early breast cancer
-
2:00
dr. zakashansky on the benefit of maintenance olaparib in brca ovarian cancer